Brevan Howard Capital Management LP Has $3.60 Million Stake in Edwards Lifesciences Corporation $EW

Brevan Howard Capital Management LP lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 41.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,272 shares of the medical research company’s stock after selling 33,100 shares during the period. Brevan Howard Capital Management LP’s holdings in Edwards Lifesciences were worth $3,599,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. True Wealth Design LLC boosted its stake in Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after acquiring an additional 259 shares during the last quarter. Rakuten Securities Inc. increased its stake in Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares in the last quarter. Hantz Financial Services Inc. increased its stake in Edwards Lifesciences by 76.6% in the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares in the last quarter. Steigerwald Gordon & Koch Inc. acquired a new stake in Edwards Lifesciences in the third quarter worth $30,000. Finally, Strengthening Families & Communities LLC acquired a new stake in Edwards Lifesciences in the third quarter worth $34,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on EW. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Tuesday, January 20th. UBS Group reaffirmed a “neutral” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. JPMorgan Chase & Co. upgraded Edwards Lifesciences from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $90.00 to $100.00 in a report on Thursday, December 18th. Piper Sandler reissued an “overweight” rating and issued a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Finally, Royal Bank Of Canada increased their price target on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, December 5th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.14.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $85.93, for a total value of $974,446.20. Following the sale, the vice president directly owned 21,266 shares in the company, valued at $1,827,387.38. The trade was a 34.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,897,284.92. This represents a 2.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 61,718 shares of company stock worth $5,236,281 over the last three months. Corporate insiders own 0.34% of the company’s stock.

Edwards Lifesciences Trading Up 2.2%

Shares of NYSE:EW opened at $83.59 on Tuesday. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The company’s fifty day simple moving average is $82.40 and its 200 day simple moving average is $81.60. The firm has a market cap of $48.55 billion, a price-to-earnings ratio of 45.68, a PEG ratio of 2.13 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company’s revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.